Cancer Alliance, NPC
What does your company do?
The Cancer Alliance is a united coalition of cancer control non-profit organisations and independent advocates, working together under a shared mandate to amplify the voice of civil society in the fight against cancer. Our core mission is to serve as a collaborative platform that drives collective advocacy, policy influence, and systemic change. We are committed to ensuring that every adult and child affected by cancer in South Africa has access to equitable, timely, and quality care—regardless of geography, income, or background. By speaking with one voice, we strive to transform the cancer care landscape and uphold the rights and dignity of all patients.
What is your biggest success?
As a social entrepreneur, I led a groundbreaking legal intervention addressing the cancer radiation crisis at Charlotte Maxeke Hospital, alongside Section27. Over 3,000 patients—many of them women—waited over three years for lifesaving treatment. Despite R784 million allocated in 2023, R250 million was returned unspent in 2024 with not a single patient treated. Our case resulted in a historic March 2025 ruling declaring the Gauteng Health Department’s inaction “unlawful and unconstitutional.” This victory is the first since the 1997 Soobramoney case to affirm the state’s duty in the progressive realisation of health rights. It also reinforces Civil Society’s right to hold government accountable, as outlined in Section 195 of the Constitution. This impact is the culmination of tireless advocacy since 2018—driven by a deep commitment to justice, equity, and the belief that access to healthcare is a fundamental right.
What has been your biggest hurdle?
Since stepping into the role of Director of Cancer Alliance in 2021—as a full-time volunteer—my biggest hurdle has been navigating the harsh reality that cancer is not recognised as a priority disease in South Africa, unlike HIV/AIDS or TB. This has significantly limited access to Corporate Social Investment funding, forcing cancer organisations like ours to rely heavily on public donations. Grant opportunities, both locally and internationally, are scarce. We have also made a conscious decision not to accept funding from pharmaceutical companies to maintain our independence and credibility. Operating with minimal financial resources while producing evidence-based advocacy reports, sustaining organisational operations, and building a unified national voice for cancer patients has been an ongoing challenge. Yet, despite these obstacles, our commitment to integrity, justice, and long-term impact has never wavered. Leading this work with resilience and purpose, even without a salary, is both my greatest challenge and proudest commitment.
